Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis

Neoplasma

Volumn 55, Issue 1, 2008, Pages 42-46

  Kubatka, P ^a   Sadlonova, V ^a   Kajo, K ^a   Nosalova, G ^a   Fetisovova, Z ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Aromatase inhibitors; Chemoprevention; Letrozole; Mammary carcinogenesis; Rat

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLNITROSOUREA; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; FOOD INTAKE; MAMMARY GLAND; NONHUMAN; PREMENOPAUSE; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA ATROPHY; WEIGHT GAIN; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; EVALUATION; EXPERIMENTAL NEOPLASM; MENOPAUSE;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MENOPAUSE; METHYLNITROSOUREA; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 48049102615     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. GOSS PE, INGLE JN, MARTINO S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802. (Pubitemid 37362955)
2. THÜRLIMANN BJ, KESHAVIAH A, COATES AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757. (Pubitemid 43016814)
3. MOURIDSEN H, SUN Y, GERSHANOVICH M, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 2004; 9: 489-496.
4. BAUM M, BUZDAR A, CUZICK J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysis. Cancer 2003; 98: 1802-1810.
5. COOMBES RC, HALL E, GIBSON LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. (Pubitemid 38298988)
6. SANTEN RJ, SAMOJLIK E, WELLS SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980; 51: 473-477.
7. SANTEN RJ, MARTEL J, HOAGLAND F, et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994; 79: 627-632.
8. BERNSTEIN LM, LARIONOV AA, KYSHTOOBAEVA AS, et al. Aromatase in breast cancer tissue localization and relationship with reproductive status of patients. J Cancer Res Clin Oncol 1996; 122: 495-498.
9. BULUN SE, SHARDA G, RINK J, et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metabol 1996; 91: 1273-1277. (Pubitemid 26084463)
10. YUE W, WANG JP, HAMILTON CJ, et al. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927-932.
11. WYSOWSKI DK, COMSTOCK GW, HELSING KJ, et al. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987; 125: 791-799. (Pubitemid 17066478)
12. TONIOLO PG, LEVITZ M, ZELENIUCH-JACQUOTTE A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-197.
13. DORGAN JF, LONGCOPE C, STEPHENSON Jr HE, et al. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 1997; 105: 583-585. (Pubitemid 27246420)
14. SANTEN RJ, YUE W, NAFTOLIN F, et al. The potential of aromatase inhibitors in breast cancer prevention. Endocr Rel Cancer 1999; 6: 235-243. (Pubitemid 29260058)
15. GOSS PE, STRASSER K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 2767.
16. FREEDMAN OC, VERMA S, CLEMONS MJ. Pre-menopusal breast cancer and aromatase inhibitors: treating a new generation of women. Breast Cancer Res Treat 2006; 99: 241-247. (Pubitemid 44337915)
17. RUSSO J, RUSSO IH, ROGERS AE, et al. Pathology of tumors in laboratory animals. Tumors of the rat. Tumors of the mammary gland. IARC Sci Publ 1990; 99: 47-78.
18. BHATNAGAR AS, BATZL C, HAUSLER A, et al. The role of estrogen in the feedback-regulation of follicle-stimulating-hormone secretion in the female rat. J Steroid Biochem Mol Biol 1993; 47: 161-166.
19. SINHA S, KASETA J, SANTNER SJ, et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998; 48: 45-51.
20. WASAN KM, GOSS PE, PRITCHARD PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16: 707-715. (Pubitemid 40767090)
21. GOSS PE, QI S, JOSSE RG, PRITZKER KPM, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34: 384-392.
22. VARMA M, CHAI JK, MEGUID MM, et al. Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav 1999; 68: 99-107.
23. PELLEYMOUNTER MA, BAKER MB, McCALEB M. Does estradiol mediate leptin's effects on adiposity and body weight? Am J Physiol 1999; 276: E955-E963.